Compare Amgen, Inc. (AMGN) vs ARK Space & Defense Innovation ETF (ARKX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs ARK Space & Defense Innovation ETF — how do they compare? Amgen, Inc. trades at $416.14 (market cap $224.14B), while ARK Space & Defense Innovation ETF trades at $34.7. The key difference: Amgen, Inc. pays a 2.43% dividend while ARK Space & Defense Innovation ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, ARK Space & Defense Innovation ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | ARKX | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $417.20 | $37.74 |
52-Week Low | $271.18 | $25.46 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
ARK Space & Defense Innovation ETF (ARKX) trades at $34.8, up 1.13% today, with a bullish technical signal driven by strong moving average alignment. The ETF focuses on space economy exposure, including holdings like SpaceX (8.31%) and Rocket Lab (6.27%), benefiting from growing commercial and defense space investments. Recent news highlights competition with other space ETFs and the impact of SpaceX's IPO on the sector.
Outlook remains positive due to thematic tailwinds in space innovation, but high volatility and stretched valuations in key holdings pose risks. Investors gain diversified access to a high-growth theme, though expense ratios and sector concentration require careful consideration amid market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →
